Related Experiment Video
Updated: Jan 28, 2026

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Antidiabetic Medications and the Risk of Endometrial Cancer in Patients
Jing Tian1,2, Yuan Liang2, Pengpeng Qu3
1Graduate School of Tianjin Medical University, Tianjin, China.
Background:
Recent epidemiological studies suggest that antidiabetic medications (ADMs) may reduce the risks of cancer and cancer mortality among patients with type 2 diabetes. However, data on its effect on endometrial cancer (EC) are unclear. In this systematic review and meta-analysis, we evaluated the association between metformin, sulfonylureas (SUs), insulin, and the risk of EC in patients with diabetes mellitus (DM).
Methods:
Studies were identified from PubMed and EMBASE database through October 2017. Observational studies reporting relative risks OR or provided data for their estimation were selected. Summary OR estimates with 95% CIs were estimated using the random-effects model.
Results:
Six studies (2 retrospective cohorts and 4 case-control trials) reported 4,739 cases of EC in 510,344 patients with DM. Meta-analysis of observational studies showed no significant association between metformin (n = 6 studies; unadjusted OR 1.15; 95% CI 0.70-1.88; p = 0.59), SUs (unadjusted OR 1.11, 95% CI 0.94-1.32, p = 0.23), or insulin (n = 3 studies; unadjusted OR 1.15; 95% CI 0.93-1.40; p = 0.19) use and risk of developing EC. However, when we do heterogeneity and sensitivity analysis, the use of metformin was associated with an increased incidence of endometrial EC compared to no metformin use (unadjusted OR 1.29; 95% CI 1.16-1.44; p < 0.01).
Conclusion:
Our data indicate that metformin, SUs, and insulin did not meaningfully affect the risk of EC. Further investigation is warranted.
Insights
Antidiabetic medications like metformin, sulfonylureas, and insulin do not appear to increase endometrial cancer risk in type 2 diabetes patients. However, further research is needed to confirm these findings.
Area of Science:
- Endocrinology
- Oncology
- Epidemiology
Background:
- Antidiabetic medications (ADMs) may influence cancer risk, but their effect on endometrial cancer (EC) is uncertain.
- Existing data on ADMs and EC risk in type 2 diabetes mellitus (DM) patients are inconclusive.
Purpose of the Study:
- To systematically review and meta-analyze the association between metformin, sulfonylureas (SUs), and insulin use and the risk of developing EC in patients with DM.
Main Methods:
- A systematic search of PubMed and EMBASE databases was conducted up to October 2017.
- Observational studies reporting relative risks (RR) or odds ratios (OR) were included.
- Random-effects models were used to estimate summary ORs with 95% confidence intervals (CIs).
Main Results:
- Six studies comprising 4,739 EC cases in 510,344 DM patients were analyzed.
- Initial meta-analysis showed no significant association between metformin, SUs, or insulin and EC risk.
- However, sensitivity analysis indicated metformin use was associated with an increased incidence of EC (unadjusted OR 1.29; 95% CI 1.16-1.44).
Conclusions:
- Metformin, SUs, and insulin did not demonstrate a significant impact on EC risk in the overall analysis.
- Metformin use warrants further investigation due to potential association with increased EC incidence in sensitivity analyses.
- Additional research is necessary to clarify the relationship between ADMs and endometrial cancer risk.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Related Concept Videos
Relative Risk
Inhaled Medications
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Endocarditis III: Medical Management
Myocarditis III: Medical Management
Pericarditis III: Medical Management